Amarantus Bioscience Holdings Inc (AMBS)

[breezy1]

Lets add some "what if information" to this:

Looks like 45 days to blast off Or Beginning of September some news.


-- WHAT IF Near Term significant value to LymPro occurs

The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter;

-- WHAT IF - after the 12 week Study a J&J partnership occurs
with J&J or Similar company takes a 50 million Stake in Company.


We project a partnership agreement for LymPro will follow shortly after the completion of the LP-002 study, and the Company is weighing strategic options which include a potential ‘spin-out’ of our diagnostics division (which includes LymPro and NuroPro);

-- WHAT IF the CLIA goes off Perfectly at "J&J or similiar" lab.

We intend to initiate the CLIA certification process for LymPro in the very immediate future at our prospective partner’s laboratory. The initial 12-week process is designed to prepare the analytical performance package (APP) that will be the basis of LymPro’s utility going forward.

WHAT IF - New Clinical Trials begin for Eltoprazine,

We expect significant announcements to begin regarding our mid-clinical stage therapeutic program Eltoprazine, including the initiation of our 200 patient Phase 2b clinical trial for Parkinson’s disease Levadopa-Induced Dyskinesia (PD-LID);

- See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/preparing-amarantus-list-2h-14-capital-markets-strategy/#sthash.Ym1y95c1.dpuf